Sign in
LXEO Stock Price, Chart, Stats & News
Lexeo Therapeutics, Inc. Common Stock
Save
383.97M
Market cap
–
Current P/E
–
Forward P/E
LXEO chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -72.97% |
ROE | -90.49% |
D/E | 0.07x |
Interest coverage ratio | -816.71x |
LXEO valuation
P/E | – |
P/S | – |
P/B | 2.76x |
P/CF | -3.12x |
P/FCF | -3.72x |
P/OCF | -3.12x |
PEG | -0.18x |
EV multiple | -4.20x |
About
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations.
Similar securities
Based on sector and market capitalization
Report issue